Ghent University Academic Bibliography

Show Sort by

Your filters: cql: parent exact "JOURNAL OF CLINICAL ONCOLOGY"

Add to list
- Conference Paper
- C3
Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer : preliminary results

Peter Van Dam, Yannick Verhoeven, Jorrit De Waele, Julie Jacobs, Pieter-Jan Van Dam, Mark Kockx, Koen Van de Vijver (UGent) , Martin Lammens, An Wouters, Evelien Smits, et al.

(2020) JOURNAL OF CLINICAL ONCOLOGY. 38(15).
Add to list
- Conference Paper
- C3
Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Ben Tran, Lisa Horvath, Matthew Rettig, Karim Fizazi, Martijn P. Lolkema, Tanya B. Dorff, Richard Greil, Jean-Pascal H. Machiels, Karen A. Autio, Sylvie Rottey (UGent) , et al.

(2020) JOURNAL OF CLINICAL ONCOLOGY. 38(15).
Add to list
- Journal Article
- A1
- open access
Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study

Keith Holmes, Ulrike Pötschger, Andrew D. J. Pearson, Sabine Sarnacki, Giovanni Cecchetto, Javier Gomez-Chacon, Roly Squire, Enrique Freud, Adam Bysiek, Lucas Matthyssens (UGent) , et al.

(2020) JOURNAL OF CLINICAL ONCOLOGY. 38(25). p.2902-2916
Add to list
Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

Xin Yang, Goska Leslie, Alicja Doroszuk, Sandra Schneider, Jamie Allen, Brennan Decker, Alison M. Dunning, James Redman, James Scarth, Inga Plaskocinska, et al.

(2020) Journal of Clinical Oncology. 38(7). p.674-687
Add to list
Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial

Simone N. Koole, Christiaan van Lieshout, Willemien J. van Driel, Evi van Schagen, Karolina Sikorska, Jacobien M. Kieffer, Jules H. Schagen van Leeuwen, Henk W.R. Schreuder, Ralph H. Hermans, Ignace H. de Hingh, et al.

(2019) Journal of Clinical Oncology. 37(23). p.2041-2050
Add to list
- Journal Article
- A1
- open access
Has the PROPHECY of AR-V7 been fulfilled?

Bram De Laere, Piet Ost (UGent) , Henrik Gronberg and Johan Lindberg

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(24). p.2181-2182
Add to list
Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study

Emmanuel Bachy, John F. Seymour, Pierre Feugier, Fritz Offner (UGent) , Armando Lopez-Guillermo, David Belada, Luc Xerri, John V. Catalano, Pauline Brice, Francois Lemonnier, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(31). p.2815-2824
Add to list
- Conference Paper
- C3
Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)

John G. Gribben, Koji Izutsu, Nathan Hale Fowler, Xiaonan Hong, Huilai Zhang, Fritz Offner (UGent) , Adriana A. S. Scheliga, Grzegorz S. Nowakowski, Antonio Pinto, Francesca Re, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(15).
Add to list
- Conference Paper
- C3
Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.

Fritz Offner (UGent) , Tadeusz Robak, Ann Janssens, Govind Babu Kanakasetty, Janusz Kloczko, Sebastian Grosicki, Jiri Mayer, Panagiotis Panagiotidis, Anna Schuh, Andrew Pettitt, et al.

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(15).
Add to list
- Conference Paper
- C3
Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple negative breast cancer (TNBC) or colorectal cancer (CRC).

J. Randolph Hecht, Arlene Chan, Miguel Martin, Nicolas Mach, Sara A. Hurvitz, Sylvie Rottey (UGent) , Uwe Pelzer, Chunxu Liu and Emily Chan

(2019) JOURNAL OF CLINICAL ONCOLOGY. 37(4).

Academic Bibliography

Uncovering the immune-modulating role of anti-RANKL therapy for cervical cancer : preliminary results

Phase I study of AMG 160, a half-life extended bispecific T-cell engager (HLE BiTE immune therapy) targeting prostate-specific membrane antigen, in patients with metastatic castration-resistant prostate cancer (mCRPC).

Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma : a report from the HR-NBL1/SIOPEN study

Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial

Has the PROPHECY of AR-V7 been fulfilled?

Sustained progression-free survival benefit of rituximab maintenance in patients with follicular lymphoma : long-term results of the PRIMA study

Efficacy and time to next treatment following lenalidomide/rituximab (R-2) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT)

Long-term follow-up of previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) treated with ofatumumab (OFA) and chlorambucil (CHL) : final analysis of the phase 3 COMPLEMENT 1 trial.

Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple negative breast cancer (TNBC) or colorectal cancer (CRC).

Contents

Support

Contact